Longeveron Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $26.9M
- Price
- $0.85
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.63%
- Volume
- 770.4K
About
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
Quick stats
Shares outstanding31.6M
Computed float27.7M
Float / shares87.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001721484
Websitehttps://www.longeveron.com
AI Summary
AI-generated1/21
minorneutralexecutive change
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
Longeveron appointed Nirav Jhaveri as Chief Financial Officer, bringing over 25 years of experience in capital markets and biotech finance.
Mr. Jhaveri replaces Marie Washburn, who returns to her role as Corporate Controller after serving as interim CFO.
The company also noted that top-line results from its Phase 2b trial of laromestrocel for HLHS are anticipated in September.